Collagen Corp. and ABC's 20/20
This article was originally published in The Gray Sheet
Executive Summary
At a March 30 session of the HIMA annual meeting, John Stossel, reporter for the ABC television program 20/20, said he will consider doing a story that provides data from studies indicating that use of Collagen's Zyderm/Zyplast injectable collagen products is not associated with autoimmune disease. A Stossel report on the Feb. 22, 1991 broadcast of 20/20 highlighted claims from individuals who believe that Collagen's products have caused autoimmune disorders ("The Gray Sheet" March 4, 1991, p. 6). Noting that plaintiffs attorneys told him that use of Collagen's products "would lead to all kinds of autoimmune disease," Stossel told the HIMA gathering that "given that the product is in a lot of places, you would think [autoimmune disease] would start showing up all over, and so far it hasn't. And if that continues down the road, and collagen is widely accepted, then I think...I should do a followup story" on how "the emphasis of our story was wrong".
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.